Brilacidin has been on ice with ABBBSI but not otherwise.
My country bumpkin take on Brilacidin goes like this:
There where some doubts raised (unfounded or not, I think all resolvable) about B in ABBBSI. Resolving them would have and will take time plus a few large trials to the tune of 30 to 40 M$. Leo & Co knew they did not have, nor would they be able to attract that kind of money at that stage. They got smart and took the backdoor in - prove Brilacidin value/efficacy elsewhere. That would make B more attractive and reduce financial risk associated with ABBBSI trials. That has been done now.